Pomerantz Law Firm Initiates Class Action Against Nektar Therapeutics Over Securities Violations
On March 19, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against Nektar Therapeutics, a prominent biopharmaceutical firm, and certain of its executives. This legal action has been registered under docket number 26-cv-01951 in the United States District Court for the Northern District of California. The lawsuit is filed on behalf of all individuals and organizations, termed as the 'Class,' who acquired Nektar securities from February 26, 2025, to December 15, 2025, inclusive. The primary aim of the class action is to recover damages arising from alleged violations of federal securities laws by the defendants, including Nektar and specific high-ranking officials.
Investors who hold Nektar securities and suffered losses during this period are prompted to submit a request by May 5, 2026, to potentially become the Lead Plaintiff in this case. Interested investors can obtain further details about the complaint on Pomerantz's official website and are encouraged to reach out for discussions regarding the action. To facilitate this, Danielle Peyton of Pomerantz LLP is available for contact at [email protected] or at 646-581-9980.
Nektar Therapeutics specializes in the development of therapies designed to selectively modulate the immune system, particularly focusing on treating autoimmune disorders. Their leading candidate, rezpegaldesleukin (also referred to as REZPEG or NKTR-358), is positioned as a first-in-class therapeutic for conditions like alopecia areata. March 2024 marked the commencement of their Phase 2b REZOLVE-AA trial. This trial aimed to assess rezpegaldesleukin's effectiveness in ninety-four patients suffering from severe variants of alopecia areata who had not previously been treated with Janus kinase inhibitors or other biologics.
The enrollment criteria for this trial were quite stringent, requiring participants to meet specific thresholds of severity and stability concerning their condition. However, the lawsuit alleges that the defendants made misleading statements regarding compliance with trial protocols, implying that the trial's integrity was compromised. Despite claims of adherence to guidelines, it appears that the enrollment process may not have followed necessary standards, potentially jeopardizing the reliability of trial outcomes.
Defendants were also accused of inflating the prospects of the ongoing REZOLVE-AA trial by projecting unnecessary optimism and failing to disclose critical information about the integrity of trial enrollment practices. As the class action indicates, the purported misrepresentations about the company's operations not only misled investors but also artificially boosted the stock's value.
December 16, 2025, witnessed the revelation of the trial's subpar results, which Nektar attributed to the inclusion of ineligible patients in the study, leading to a sharp drop in the company’s stock price by 7.77%. This decline further emphasizes the consequences of the alleged miscommunication by Nektar's executives. The impact of the lawsuit could potentially be significant, retrieving damages for affected investors who trusted the company's assurances but were later faced with disappointing news.
Founded by the distinguished Abraham L. Pomerantz, Pomerantz LLP has established itself as a leading firm in the realm of class action lawsuits, particularly those related to securities and corporate accountability. With over 85 years of experience, the firm has a commendable track record of advocating for victims of securities fraud and corporate misconduct.
As this case unfolds, it may not only reshape investor relations for Nektar but also signal a critical moment for holding corporate entities accountable for misleading practices in clinical trials. Investors who believe they may qualify for the class action are urged to act swiftly in light of the deadlines, ensuring that their voices can be heard in the ongoing legal proceedings.
Investors who hold Nektar securities and suffered losses during this period are prompted to submit a request by May 5, 2026, to potentially become the Lead Plaintiff in this case. Interested investors can obtain further details about the complaint on Pomerantz's official website and are encouraged to reach out for discussions regarding the action. To facilitate this, Danielle Peyton of Pomerantz LLP is available for contact at [email protected] or at 646-581-9980.
Nektar Therapeutics specializes in the development of therapies designed to selectively modulate the immune system, particularly focusing on treating autoimmune disorders. Their leading candidate, rezpegaldesleukin (also referred to as REZPEG or NKTR-358), is positioned as a first-in-class therapeutic for conditions like alopecia areata. March 2024 marked the commencement of their Phase 2b REZOLVE-AA trial. This trial aimed to assess rezpegaldesleukin's effectiveness in ninety-four patients suffering from severe variants of alopecia areata who had not previously been treated with Janus kinase inhibitors or other biologics.
The enrollment criteria for this trial were quite stringent, requiring participants to meet specific thresholds of severity and stability concerning their condition. However, the lawsuit alleges that the defendants made misleading statements regarding compliance with trial protocols, implying that the trial's integrity was compromised. Despite claims of adherence to guidelines, it appears that the enrollment process may not have followed necessary standards, potentially jeopardizing the reliability of trial outcomes.
Defendants were also accused of inflating the prospects of the ongoing REZOLVE-AA trial by projecting unnecessary optimism and failing to disclose critical information about the integrity of trial enrollment practices. As the class action indicates, the purported misrepresentations about the company's operations not only misled investors but also artificially boosted the stock's value.
December 16, 2025, witnessed the revelation of the trial's subpar results, which Nektar attributed to the inclusion of ineligible patients in the study, leading to a sharp drop in the company’s stock price by 7.77%. This decline further emphasizes the consequences of the alleged miscommunication by Nektar's executives. The impact of the lawsuit could potentially be significant, retrieving damages for affected investors who trusted the company's assurances but were later faced with disappointing news.
Founded by the distinguished Abraham L. Pomerantz, Pomerantz LLP has established itself as a leading firm in the realm of class action lawsuits, particularly those related to securities and corporate accountability. With over 85 years of experience, the firm has a commendable track record of advocating for victims of securities fraud and corporate misconduct.
As this case unfolds, it may not only reshape investor relations for Nektar but also signal a critical moment for holding corporate entities accountable for misleading practices in clinical trials. Investors who believe they may qualify for the class action are urged to act swiftly in light of the deadlines, ensuring that their voices can be heard in the ongoing legal proceedings.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.